These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 17018329)

  • 1. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
    Elkind AH; O'Carroll P; Blumenfeld A; DeGryse R; Dimitrova R;
    J Pain; 2006 Oct; 7(10):688-96. PubMed ID: 17018329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
    Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C;
    Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM; Schim JD; Chippendale TJ
    Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study.
    Millán-Guerrero RO; Isais-Millán S; Barreto-Vizcaíno S; Rivera-Castaño L; Rios-Madariaga C
    Eur J Neurol; 2009 Jan; 16(1):88-94. PubMed ID: 19087155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acupoint injection of onabotulinumtoxin A for migraines.
    Hou M; Xie JF; Kong XP; Zhang Y; Shao YF; Wang C; Ren WT; Cui GF; Xin L; Hou YP
    Toxins (Basel); 2015 Oct; 7(11):4442-54. PubMed ID: 26529014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
    Silberstein S; Mathew N; Saper J; Jenkins S
    Headache; 2000 Jun; 40(6):445-50. PubMed ID: 10849039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.
    Silberstein SD; Göbel H; Jensen R; Elkind AH; Degryse R; Walcott JM; Turkel C
    Cephalalgia; 2006 Jul; 26(7):790-800. PubMed ID: 16776693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.
    Evers S; Vollmer-Haase J; Schwaag S; Rahmann A; Husstedt IW; Frese A
    Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M; Dover J; Maas C; Nestor M
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
    Schlessinger J; Monheit G; Kane MA; Mendelsohn N
    Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Stark SR; Lucas SM; Christie SN; Degryse RE; Turkel CC;
    Mayo Clin Proc; 2005 Sep; 80(9):1126-37. PubMed ID: 16178492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
    Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.